Drugs that contain Loteprednol Etabonate
1. List of Eysuvis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219596 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10857096 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10945948 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10940108 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10993908 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10646436 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 26, 2023 |
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the eye of a patient for treatment of dry eye condition
Dosage: SUSPENSION/DROPS;OPHTHALMIC
2. List of Inveltys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393213 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9056057 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9532955 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US10058511 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US11219597 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10864219 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US9737491 | KALA PHARMS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(10 years from now) | |
| US9827191 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10688045 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
| US10646437 | KALA PHARMS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(10 years from now) | |
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for treating inflammation and/or other disorders in an eye of a patient
Dosage: SUSPENSION/DROPS;OPHTHALMIC
3. List of Lotemax Sm drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Strength (NS) | Feb 22, 2022 |
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic